
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 853 | 827 | 893 | 1443 | 3330 | 4725 |
Fund Return | -14.73% | -17.34% | -10.71% | 13.01% | 27.2% | 16.8% |
Place in category | 88 | 163 | 147 | 71 | 1 | 5 |
% in Category | 55 | 93 | 98 | 82 | 1 | 12 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Quant Active Fund Growth | 87.67B | -14.89 | 11.67 | 15.90 | ||
INF966L01911 | 61.89B | -12.32 | 17.53 | 17.94 | ||
INF966L01200 | 30.04B | -8.99 | 18.01 | 15.91 | ||
INF966L01580 | 30.04B | -8.80 | 19.81 | 16.67 | ||
INF966L01820 | 16.03B | 1.18 | 6.62 | 6.70 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Reliance Equity Opportunities Bonus | 353.53B | -13.20 | 21.28 | 12.52 | ||
Reliance Equity Opportunities Div | 353.53B | -13.67 | 20.42 | 12.03 | ||
Reliance Equity Opportunities Gr | 353.53B | -13.20 | 21.28 | 12.52 | ||
Reliance Equity Opportunities DirGr | 353.53B | -13.09 | 22.22 | 13.35 | ||
Reliance Equity Opportunities DirDi | 353.53B | -13.53 | 21.65 | 13.10 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Reliance Industries | INE002A01018 | 10.46 | 1,252.60 | -1.76% | |
Aurobindo Pharma | INE406A01037 | 5.10 | 1,134.15 | -2.27% | |
ITC | INE154A01025 | 4.40 | 406.65 | -0.76% | |
Larsen & Toubro | INE018A01030 | 3.96 | 3,436.80 | -1.59% | |
Aegis Logistics Ltd | INE208C01025 | 3.75 | 781.80 | -2.94% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Sell | Neutral |
Technical Indicators | Strong Buy | Strong Sell | Strong Sell |
Summary | Neutral | Strong Sell | Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review